Virax Biolabs Group (VRAX) Institutional Ownership → This company has increased its dividend every year for 54 years (From DTI) (Ad) Free VRAX Stock Alerts $0.68 -0.01 (-1.45%) (As of 04/18/2024 ET) Add Compare Share Share OwnershipStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Virax Biolabs Group (NASDAQ:VRAX)CurrentInstitutional OwnershipPercentage8.61%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$10.61MNumber ofInstitutional Sellers(last 12 months)0 Get VRAX Insider Trade Alerts Want to know when executives and insiders are buying or selling Virax Biolabs Group stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data VRAX Institutional Buying and Selling by Quarter Ad Paradigm PressAI “wealth window” is closing soon!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… Virax Biolabs Group Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/13/2024Armistice Capital LLC121,999$178K0.0%N/A7.871% 5/16/2023Armistice Capital LLC1,500,000$1.04M0.0%N/A9.648% 2/15/2023Virtu Financial LLC48,458$35K0.0%N/A0.378% 2/15/2023Legal & General Group Plc102,608$73K0.0%N/A0.800% 11/10/2022UBS Group AG12,196$38K0.0%N/A0.107% (Data available from 1/1/2016 forward) VRAX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of VRAX shares? During the previous two years, the following institutional investors and hedge funds held shares of Virax Biolabs Group shares: Armistice Capital LLC ($178K), Legal & General Group Plc ($73K), and UBS Group AG ($38K), Virtu Financial LLC ($35K).Learn more on VRAX's institutional investors. What percentage of Virax Biolabs Group stock is owned by institutional investors? 8.61% of Virax Biolabs Group stock is owned by institutional investors. Learn more on VRAX's institutional investor holdings. Which institutional investors have been buying Virax Biolabs Group stock? The following institutional investors have purchased Virax Biolabs Group stock in the last 24 months: Armistice Capital LLC ($1.62M), Legal & General Group Plc ($102.61K), Virtu Financial LLC ($48.46K), and UBS Group AG ($12.20K). How much institutional buying is happening at Virax Biolabs Group? Institutional investors have bought a total of 1,785,261 shares in the last 24 months. This purchase volume represents approximately $12.10M in transactions. Related Companies: Baudax Bio Institutional Ownership TC Biopharm Institutional Ownership Acorda Therapeutics Institutional Ownership Invitae Institutional Ownership 9 Meters Biopharma Institutional Ownership Ampio Pharmaceuticals Institutional Ownership Aptevo Therapeutics Institutional Ownership CNS Pharmaceuticals Institutional Ownership NeuBase Therapeutics Institutional Ownership Neptune Wellness Solutions Institutional Ownership This page (NASDAQ:VRAX) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & CompanyOptions trading has suddenly become more reliable.Eagle Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.